TherapeuticsMD
TXMD
149 hedge funds and large institutions have $98.2M invested in TherapeuticsMD in 2021 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 49 increasing their positions, 35 reducing their positions, and 23 closing their positions.
96% more call options, than puts
Call options by funds: $1.09M | Put options by funds: $558K
40% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 35
0.24% less ownership
Funds ownership: 0.87% → 0.63% (-0.24%)
3% less funds holding
Funds holding: 154 → 149 (-5)
13% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 23
52% less capital invested
Capital invested by funds: $204M → $98.2M (-$105M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$2.26M |
| 2 |
Renaissance Technologies
New York
|
+$1.32M |
| 3 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$904K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$728K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$425K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.3M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.3M |
| 3 |
Axa
Paris,
France
|
-$5.44M |
| 4 |
BAMCO Inc
New York
|
-$4.56M |
| 5 |
SAM
Storebrand Asset Management
Lysaker,
Norway
|
-$3.41M |
TXMD Hedge Fund Activity: Q3 2021 in Review
149 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q3 2021, worth a combined $98.2M — down 52% from $204M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of TXMD and 20 opened new positions — a net loss of 3 holders — while 35 trimmed existing stakes and 49 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $2.26M. The largest seller was T. Rowe Price Associates, cutting an estimated $16.3M.
- 149 institutional investors held TherapeuticsMD (TXMD) as of Q3 2021, down from 154 in Q2 2021.
- Funds reported $98.2M of TherapeuticsMD stock for Q3 2021, down 52% quarter-over-quarter.
- 20 funds opened new TherapeuticsMD positions in Q3 2021 and 23 closed out, a net change of -3 holders.
- The largest TherapeuticsMD buyer in Q3 2021 was Rubric Capital Management (New York), an estimated $2.26M added.
- The largest TherapeuticsMD seller in Q3 2021 was T. Rowe Price Associates, an estimated $16.3M sold.
Based on aggregated 13F filings for Q3 2021.